Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Zai Lab Ltd.

Bristol Gets Tumor-Agnostic Second Approval For Augtyro

Already approved for lung cancer, BMS’s ROS1/NTKK inhibitor gets US FDA accelerated approval for solid tumors that are NTRK-fusion positive.

Approvals Business Strategies

China In-Licensing Crossroads: Zai Lab, Everest March Towards Market But BioNova Returns Rights

China's Zai Lab and Everest are still pursuing profitability on the commercialization of in-licensed assets, while BioNova and others have already bowed out of the game.

China Business Strategies

As Vyvgart Surges To Blockbuster Status, Argenx Maps Out Expansion Plans

The European biotech is just getting started with its expansion plans for the drug in generalized myasthenia gravis, while multiple readouts in new autoimmune diseases are expected in 2024.

Immune Disorders Commercial

Mixed Q3 For China's Innovative Firms Amid Anti-Graft Campaign

China's research-based pharma companies reported mixed third-quarter results for their anti-PD-1 antibodies, BTK and PARP inhibitors amid broader challenges including an ongoing government-led anti-corruption campaign.

China Sales & Earnings
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Zai Lab Limited
    • Zai Lab (Shanghai) Co., Ltd.
UsernamePublicRestriction

Register